Neurodegenerative Disease Management

metrics 2024

Championing Excellence in Neurological Research

Introduction

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

Metrics 2024

SCIMAGO Journal Rank0.62
Journal Impact Factor2.30
Journal Impact Factor (5 years)2.60
H-Index32
Journal IF Without Self2.30
Eigen Factor0.00
Normal Eigen Factor0.18
Influence0.61
Immediacy Index0.60
Cited Half Life6.10
Citing Half Life7.50
JCI0.59
Total Documents411
WOS Total Citations865
SCIMAGO Total Citations2044
SCIMAGO SELF Citations28
Scopus Journal Rank0.62
Cites / Document (2 Years)2.59
Cites / Document (3 Years)2.45
Cites / Document (4 Years)2.74

Metrics History

Rank 2024

Scopus

Neurology (clinical) in Medicine
Rank #180/400
Percentile 55.00
Quartile Q2

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 146/277
Percentile 47.50
Quartile Q3

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 176/278
Percentile 36.69
Quartile Q3

Quartile History

Similar Journals

NEUROCHEMISTRY INTERNATIONAL

Connecting Researchers to Transform Neurochemical Understanding
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0197-0186Frequency: 10 issues/year

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

METABOLIC BRAIN DISEASE

Transforming understanding of brain metabolism.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0885-7490Frequency: 6 issues/year

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.

Journal of Central Nervous System Disease

Connecting clinical insights with molecular breakthroughs.
Publisher: SAGE PUBLICATIONS LTDISSN: 1179-5735Frequency: 1 issue/year

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

REVISTA DE NEUROLOGIA

Exploring the Frontiers of Neurology and Medicine
Publisher: REVISTA DE NEUROLOGIAISSN: 0210-0010Frequency: 12 issues/year

REVISTA DE NEUROLOGIA is a distinguished academic journal focusing on the broad fields of neurology and medicine, published in Spain since its inception in 1959. The journal plays a vital role in disseminating significant research findings, clinical studies, and advancements in neurological science, catering to an audience of researchers, clinicians, and students alike. With an ISSN of 0210-0010 and an E-ISSN of 1576-6578, this quarterly publication has maintained its commitment to enhancing the understanding of neurological disorders and therapies through rigorous peer-reviewed articles. While currently not classified as open access, it is indexed in Scopus, holding a rank of #253 out of 400 in the category of Medicine (Neurology), reflecting its relevance in the field with a 36th percentile. The journal is positioned within the Q3 quartile for both Medicine (miscellaneous) and Clinical Neurology categories as of 2023. Based in Barcelona, Spain, it is a vital resource for anyone devoted to the advancement of knowledge and practice in neurology.

Current Neuropharmacology

Exploring the frontiers of neuropharmacological research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

NEUROLOGY

Pioneering insights in the realm of neurology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0028-3878Frequency: 48 issues/year

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

NEUROLOGIA

Connecting Global Minds in the Pursuit of Neurological Excellence
Publisher: ELSEVIER ESPANA SLUISSN: 0213-4853Frequency: 9 issues/year

NEUROLOGIA, an esteemed journal published by ELSEVIER ESPANA SLU, stands at the forefront of the field of neurology, with a dedicated focus on innovative research and clinical practice since its inception in 1973. As an Open Access journal since 2017, it champions the dissemination of knowledge, allowing researchers, professionals, and students alike to access cutting-edge findings in neurology without barriers. With an impressive Scopus rank of #115 in the clinical neurology category, placing it in the 71st percentile, NEUROLOGIA is categorized as Q3 in both general medicine and clinical neurology, reflecting its impact and relevance in a rapidly evolving field. Based in Barcelona, Spain, the journal's commitment to advancing understanding of neurological conditions is underscored by its rigorous peer-review process and engagement with a global audience. As it continues to publish vital research that shapes clinical practices and informs policy, NEUROLOGIA remains an integral resource for those striving to improve outcomes in neurology.

CURRENT OPINION IN NEUROLOGY

Shaping the Future of Clinical Neurology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1350-7540Frequency: 6 issues/year

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.

FOLIA NEUROPATHOLOGICA

Pioneering discoveries for a healthier future.
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1641-4640Frequency: 4 issues/year

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

ACTA NEUROLOGICA SCANDINAVICA

Transforming Neurological Research into Practice
Publisher: WILEYISSN: 0001-6314Frequency: 12 issues/year

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.